News stories about Audentes Therapeutics (NASDAQ:BOLD) have been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Audentes Therapeutics earned a news impact score of 0.06 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 44.9947848994813 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:
- Raymond James Financial Reiterates “Hold” Rating for Audentes Therapeutics (BOLD) (americanbankingnews.com)
- Audentes Therapeutics (BOLD) Price Target Increased to $44.00 by Analysts at BMO Capital Markets (americanbankingnews.com)
- Audentes Therapeutics Pulls Off Positive Interim Results (finance.yahoo.com)
- Biotech Stock Rockets To Record On Gene Therapy Trial In Children (finance.yahoo.com)
- Audentes Therapeutics (BOLD) PT Raised to $56.00 at Wedbush (americanbankingnews.com)
Audentes Therapeutics (NASDAQ BOLD) opened at $36.63 on Friday. The company has a market cap of $1,218.40, a PE ratio of -10.49 and a beta of -0.21. Audentes Therapeutics has a fifty-two week low of $13.90 and a fifty-two week high of $41.80.
BOLD has been the topic of a number of analyst reports. HC Wainwright initiated coverage on shares of Audentes Therapeutics in a research note on Wednesday, December 20th. They set a “buy” rating and a $37.00 price objective on the stock. Bank of America reiterated a “buy” rating and set a $33.00 price objective (up from $23.00) on shares of Audentes Therapeutics in a research note on Friday, September 22nd. BidaskClub downgraded shares of Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 6th. William Blair reiterated a “buy” rating on shares of Audentes Therapeutics in a research note on Friday. Finally, BMO Capital Markets set a $44.00 price objective on shares of Audentes Therapeutics and gave the stock a “buy” rating in a research note on Friday. Two analysts have rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Audentes Therapeutics presently has an average rating of “Buy” and a consensus target price of $35.00.
In related news, Director Louis G. Lange sold 18,000 shares of the firm’s stock in a transaction that occurred on Friday, December 22nd. The shares were sold at an average price of $30.88, for a total value of $555,840.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Suyash Prasad sold 8,000 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $28.53, for a total transaction of $228,240.00. The disclosure for this sale can be found here. Insiders sold 36,000 shares of company stock valued at $1,052,480 in the last three months. Company insiders own 47.30% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Audentes Therapeutics (BOLD) Earning Somewhat Favorable News Coverage, Study Shows” was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/01/06/audentes-therapeutics-bold-earning-somewhat-favorable-news-coverage-study-shows.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
What are top analysts saying about Audentes Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Audentes Therapeutics and related companies.